Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Clin Microbiol Infect. 2018 Jun;24(6):659.e1-659.e3. doi: 10.1016/j.cmi.2017.10.018. Epub 2017 Oct 27.
Staphylococcus aureus biofilm may constitute a major cause of virulence. Our main objective was to analyse whether there was an association between biofilm production and poor outcome in patients with S. aureus bacteraemia.
We studied 485 S. aureus strains isolated from the blood of patients with bacteraemia from 2012 to 2015. We assessed in vitro biomass production using crystal violet assay and metabolic activity using tetrazolium salt assay. Strains were classified in tertile ranks as follows: low biomass producers, moderate biomass producers, high biomass producers, low metabolic activity, moderate metabolic activity and high metabolic activity. We excluded from analysis strains with moderate crystal violet and tetrazolium salt values. We defined poor outcome as fulfillment of one or more of the following conditions: 30-day attributable mortality, infective endocarditis, persistent bacteraemia and recurrent bacteraemia.
Outcome was poor in 199 (41.0%) of 485 S. aureus bacteraemia episodes. The distribution of poor outcome with respect to biomass production and metabolic activity was as follows: low biomass producers, 36.6% vs. high biomass producers, 43.2% (p 0.26); and low metabolic activity, 43.5% vs. high metabolic activity, 36.2% (p 0.91). The presence of methicillin-resistant S. aureus was the only characteristic that was more likely to be present in the high metabolic activity group (17.4% vs. 39.3%, p < 0.001).
Biofilm production, as determined by any of the methods used in the present study, is not associated with poor outcome in patients with S. aureus bacteraemia.
金黄色葡萄球菌生物膜可能是其毒力的主要原因之一。我们的主要目的是分析金黄色葡萄球菌菌血症患者生物膜的产生与不良结局之间是否存在关联。
我们研究了 2012 年至 2015 年从菌血症患者血液中分离的 485 株金黄色葡萄球菌。我们使用结晶紫法评估体外生物量的产生,使用四唑盐法评估代谢活性。根据以下三分位等级对菌株进行分类:低生物量产生者、中生物量产生者、高生物量产生者、低代谢活性、中代谢活性和高代谢活性。我们排除了结晶紫和四唑盐值处于中等水平的菌株。我们将以下一种或多种条件的满足定义为不良结局:30 天归因死亡率、感染性心内膜炎、持续性菌血症和复发性菌血症。
485 例金黄色葡萄球菌菌血症中,199 例(41.0%)结局不良。根据生物量产生和代谢活性,不良结局的分布如下:低生物量产生者为 36.6%,高生物量产生者为 43.2%(p 0.26);低代谢活性者为 43.5%,高代谢活性者为 36.2%(p 0.91)。耐甲氧西林金黄色葡萄球菌的存在是高代谢活性组更有可能存在的唯一特征(17.4% vs. 39.3%,p < 0.001)。
本研究中使用的任何方法确定的生物膜产生与金黄色葡萄球菌菌血症患者的不良结局无关。